Optimization of Deuteron Irradiation of <sup>176</sup>Yb for Producing <sup>177</sup>Lu of High Specific Activity Exceeding 3000 GBq/mg

Optimization of Deuteron Irradiation of <sup>176</sup>Yb for Producing <sup>177</sup>Lu of High Specific Activity Exceeding 3000 GBq/mg

The irradiation of <sup>176</sup>Yb with deuterons offers a promising pathway for the production of the theranostic radionuclide <sup>177</sup>Lu. To optimize this process, calculations integrating deuteron transport, isotope production, and decay have been performed. In pure...

Full description

Bibliographic Details
Main Author:	Lin Shao
Format:	Article
Language:	English
Published:	MDPI AG 2023-08-01
Series:	Molecules
Subjects:	isotope production theranostic radionuclide accelerator lutetium cancer treatment medical isotope
Online Access:	https://www.mdpi.com/1420-3049/28/16/6053

Similar Items

Effect of <i>N</i>-Terminal Peptide Modifications on In Vitro and In Vivo Properties of <sup>177</sup>Lu-Labeled Peptide Analogs Targeting CCK2R
by: Anton Amadeus Hörmann, et al.
Published: (2023-02-01)

Simultaneous Visualization of <sup>161</sup>Tb- and <sup>177</sup>Lu-Labeled Somatostatin Analogues Using Dual-Isotope SPECT Imaging
by: Francesca Borgna, et al.
Published: (2021-04-01)

A Step-by-Step Guide for the Novel Radiometal Production for Medical Applications: Case Studies with <sup>68</sup>Ga, <sup>44</sup>Sc, <sup>177</sup>Lu and <sup>161</sup>Tb
by: Zeynep Talip, et al.
Published: (2020-02-01)

Radionuclide Therapy of HER2-Expressing Xenografts Using [<sup>177</sup>Lu]Lu-ABY-027 Affibody Molecule Alone and in Combination with Trastuzumab
by: Yongsheng Liu, et al.
Published: (2023-04-01)

Investigation of the <sup>176</sup>Yb Interference Correction during Determination of the <sup>176</sup>Hf/<sup>177</sup>Hf Ratio by Laser Ablation and Solution Analysis on the Neoma MC-ICP-MS
by: Nasser A. Zirakparvar, et al.
Published: (2022-07-01)

Single Center Experience with a 4-Week <sup>177</sup>Lu-PSMA-617 Treatment Interval in Patients with Metastatic Castration-Resistant Prostate Cancer
by: Jukka Kemppainen, et al.
Published: (2022-12-01)

Advances in <sup>177</sup>Lu-PSMA and <sup>225</sup>Ac-PSMA Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer
by: Sui Wai Ling, et al.
Published: (2022-10-01)

Radioligand Therapy with [<sup>177</sup>Lu]Lu-DOTA-TATE or [<sup>177</sup>Lu]Lu-DOTA-TATE and [<sup>90</sup>Y]Y-DOTA-TATE in Patients with Neuroendocrine Neoplasms of Unknown Locations, or Locations Other Than the Midgut and Pancreas as Primaries in a G1, G2 and G3 Grade
by: Adam Daniel Durma, et al.
Published: (2023-08-01)

Preliminary Evaluation of Iron Oxide Nanoparticles Radiolabeled with <sup>68</sup>Ga and <sup>177</sup>Lu as Potential Theranostic Agents
by: Evangelia-Alexandra Salvanou, et al.
Published: (2022-07-01)

Features and Practical Aspects of Radiochemical Purity Determination of Receptor-Specific Lu-177 Radiopharmaceuticals as Exemplified by [<sup>177</sup>Lu]Lu–PSMA-617
by: A. A. Larenkov, et al.
Published: (2022-12-01)

The Isotopic (δ<sup>18</sup>O, δ <sup>2</sup>H, δ<sup>13</sup>C, δ<sup>15</sup>N, δ<sup>34</sup>S, <sup>87</sup>Sr/<sup>86</sup>Sr, δ<sup>11</sup>B) Composition of Adige River Water Records Natural and Anthropogenic Processes
by: Chiara Marchina, et al.
Published: (2020-05-01)

Improving Overall Survival and Quality of Life in Patients with Prostate Cancer and Neuroendocrine Tumors Using <sup>177</sup>Lu-iPSMA and <sup>177</sup>Lu-DOTATOC: Experience after 905 Treatment Doses
by: Myrna Luna-Gutiérrez, et al.
Published: (2023-07-01)

<sup>177</sup>Lu-Labeled Iron Oxide Nanoparticles Functionalized with Doxorubicin and Bevacizumab as Nanobrachytherapy Agents against Breast Cancer
by: Evangelia-Alexandra Salvanou, et al.
Published: (2024-02-01)

Discrete Convolution-Based Energy Spectrum Configuring Method for the Analysis of the Intrinsic Radiation of <sup>176</sup>Lu
by: Kilyoung Ko, et al.
Published: (2021-10-01)

Synthesis and Evaluation of <sup>177</sup>Lu-DOTA-PD-L1-i and <sup>225</sup>Ac-HEHA-PD-L1-i as Potential Radiopharmaceuticals for Tumor Microenvironment-Targeted Radiotherapy
by: Myrna Luna-Gutiérrez, et al.
Published: (2023-08-01)

Liquid Chromatography ICP-MS to Assess the Stability of <sup>175</sup>Lu- and <sup>nat</sup>Ga-Based Tumor-Targeting Agents towards the Development of <sup>177</sup>Lu- and <sup>68</sup>Ga-Labeled Radiopharmaceuticals
by: Rahel H. Wallimann, et al.
Published: (2024-02-01)

<sup>67</sup>Cu Production Capabilities: A Mini Review
by: Liliana Mou, et al.
Published: (2022-02-01)

Toxicity Assessment of [<sup>177</sup>Lu]Lu−iFAP/iPSMA Nanoparticles Prepared under GMP-Compliant Radiopharmaceutical Processes
by: Tania Hernández-Jiménez, et al.
Published: (2022-11-01)

[<sup>177</sup>Lu]Lu-PSMA-617 (Pluvicto<sup>TM</sup>): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer
by: Ute Hennrich, et al.
Published: (2022-10-01)

Prognostic Value of the De Ritis Ratio for Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [<sup>177</sup>Lu]Lu-PSMA-617 Radioligand Therapy
by: Sebastian Gaal, et al.
Published: (2023-10-01)

Clinical Variables Associated with PSA Response to Lutetium-177-PSMA ([177Lu]-PSMA-617) Radionuclide Treatment in Men with Metastatic Castration-Resistant Prostate Cancer
by: Moran Gadot, et al.
Published: (2020-04-01)

Peptide Receptor Radionuclide Therapy (PRRT) with <sup>177</sup>Lu-DOTATATE; Differences in Tumor Dosimetry, Vascularity and Lesion Metrics in Pancreatic and Small Intestinal Neuroendocrine Neoplasms
by: Ulrika Jahn, et al.
Published: (2021-02-01)

Characterization of Non-Specific Uptake and Retention Mechanisms of [<sup>177</sup>Lu]Lu-PSMA-617 in the Salivary Glands
by: Nathalie Heynickx, et al.
Published: (2023-05-01)

Comparative Preclinical Evaluation of HER2-Targeting ABD-Fused Affibody<sup>®</sup> Molecules <sup>177</sup>Lu-ABY-271 and <sup>177</sup>Lu-ABY-027: Impact of DOTA Position on ABD Domain
by: Yongsheng Liu, et al.
Published: (2021-06-01)

Therapeutic Potential of <sup>47</sup>Sc in Comparison to <sup>177</sup>Lu and <sup>90</sup>Y: Preclinical Investigations
by: Klaudia Siwowska, et al.
Published: (2019-08-01)

Synthesis, Characterization, and Therapeutic Efficacy of <sup>177</sup>Lu-DMSA@SPIONs in Nanobrachytherapy of Solid Tumors
by: Dragana Stanković, et al.
Published: (2023-07-01)

Simultaneous Determination of δ<sup>18</sup>O and δ<sup>37</sup>Cl Isotopic Compositions and the Concentrations of F, Cl, and S in Apatite Using SIMS
by: Yu Liu, et al.
Published: (2022-03-01)

Lutathera<sup>®</sup> Orphans: State of the Art and Future Application of Radioligand Therapy with <sup>177</sup>Lu-DOTATATE
by: Luca Urso, et al.
Published: (2023-03-01)

Amino Acid Solutions for <sup>177</sup>Lu-Oxodotreotide Premedication: A Tolerance Study
by: Pierre Courault, et al.
Published: (2022-10-01)

p53-Mediated Radiosensitization of <sup>177</sup>Lu-DOTATATE in Neuroblastoma Tumor Spheroids
by: Sara Lundsten, et al.
Published: (2021-11-01)

Evidence for Groundwater Salinity Origin Based on Hydrogeochemical and Isotopic (<sup>2</sup>H, <sup>18</sup>O, <sup>37</sup>Cl, <sup>3</sup>H, <sup>13</sup>C, <sup>14</sup>C) Approaches: Sousse, Eastern Tunisia
by: Farah Nefzaoui, et al.
Published: (2023-03-01)

Therapeutic Outcomes of 177Lu-PSMA Targeted Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A Single-Center Study
by: Seyed Ali Mirshahvalad, et al.
Published: (2023-01-01)

In Vivo Measurement and Characterization of a Novel Formulation of [177Lu]-DOTA-Octreotate
by: Dale Bailey, et al.
Published: (2016-01-01)

Correlations between [<sup>68</sup>Ga]Ga-DOTA-TOC Uptake and Absorbed Dose from [<sup>177</sup>Lu]Lu-DOTA-TATE
by: Ragnar Bruvoll, et al.
Published: (2023-02-01)

Evaluation of <sup>68</sup>Ga-PSMA-11 PET-MRI in Patients with Advanced Prostate Cancer Receiving <sup>177</sup>Lu-PSMA-617 Therapy: A Radiomics Analysis
by: Wolfgang Roll, et al.
Published: (2021-07-01)

Improved Tumor-Targeting with Peptidomimetic Analogs of Minigastrin <sup>177</sup>Lu-PP-F11N
by: Nathalie M. Grob, et al.
Published: (2021-05-01)

Baseline Imaging Derived Predictive Factors of Response Following [<sup>177</sup>Lu]Lu-PSMA-617 Therapy in Salvage Metastatic Castration-Resistant Prostate Cancer: A Lesion- and Patient-Based Analysis
by: Esmée C. A. van der Sar, et al.
Published: (2022-07-01)

Preparation and Preliminary Evaluation of Neurotensin Radiolabelled with <sup>68</sup>Ga and <sup>177</sup>Lu as Potential Theranostic Agent for Colon Cancer
by: Radu Anton Leonte, et al.
Published: (2021-04-01)

A Single Dose of Novel PSMA-Targeting Radiopharmaceutical Agent [<sup>177</sup>Lu]Ludotadipep for Patients with Metastatic Castration-Resistant Prostate Cancer: Phase I Clinical Trial
by: Dongho Shin, et al.
Published: (2022-12-01)

Comparative Evaluation of Novel <sup>177</sup>Lu-Labeled PNA Probes for Affibody-Mediated PNA-Based Pretargeting
by: Hanna Tano, et al.
Published: (2021-01-01)